

## **Supplementary information**

### *Microarray studies:*



U87-MG cells were stably transduced with a control plasmid or with a plasmid carrying the complete coding sequence of the CNS-specific ECM proteoglycan brevican (Genbank #BC010571). Transduced cells were cultured for two weeks and checked for expression of full-length and processed fragments of brevican before further testing (21). Control and brevican-expressing cells were gently resuspended and dissociated in DPBS, transferred to fresh culture medium and plated on poly-L-lysine- or fibronectin-coated 60-mm culture dishes at a total density of  $5 \cdot 10^5$  cells/dish. After three hours, non-adhered cells were washed and the remaining cells were quickly frozen on ethanol/dry ice and further processed in Trizol (Invitrogen) to prepare total RNA. Details of cell transduction, cell adhesion experiments and further analysis of protein expression in those cells have been previously described (21). Increased cell adhesion was observed to correlate directly with increased cell motility on the same substrate (21).

Quality of the extracted RNA was verified by capillary electrophoresis (Bioanalyzer 2100, Agilent). RNA samples were processed for hybridization to U133(+) 2.0 genechips (Affimetrix), that cover the complete human genome. Microarrays were performed in duplicate for each experimental condition (cell type X substrate). RNA hybridization, image scanning and data analysis were performed at the Functional Genomics Core Facility of Nationwide Children's Hospital (Columbus, Ohio).

**Supplementary Fig. 1:** Fibulin-3 is upregulated by combined effect of brevican and fibronectin.

A) Experimental design followed to identify altered mRNA expression in response to neural (brevican) and mesenchymal (fibronectin) ECM components. Colored boxes (4 conditions in duplicate) represent potential microarray results for probesets upregulated in substrate-dependent

(row 1), brevican-dependent (row 2) or brevican/substrate-dependent (row 3) manners. Using this assay, fibulin-3 was the only ECM-related transcript overexpressed in a brevican- and fibronectin-dependent manner (Suppl. Table I). B) Validation of fibulin-3 expression in U87-MG cells processed as indicated above, using qRT-PCR. Results indicate relative expression (Delta-Delta Ct) of fibulin-3 mRNA over baseline values (control cells on PLL substrate = 1). GAPDH was used as normalizing reference. *PLL*, poly-L-lysine; *FN*, fibronectin.



substrate:	PLL	FN	PLL	FN	
brevican:	--	--	+	+	
probeset 1					FN-dependent
probeset 2					brevican-dependent
probeset 3					FN/brevican-dependent
⋮	⋮				

**SUPPLEMENTARY  
TABLE I**

**GENES UPREGULATED BY BREVICAN AND FIBRONECTIN IN GLIOMA CELLS**

Bcan= brevican  
FN= fibronectin  
PLL= poly-L-Lysine

The table indicates transcripts that were upregulated in a brevican- and fibronectin-dependent manner

Mean values for each condition (brevican vs control cells, plated on FN or PLL) were normalized to the baseline values of control cells plated on PLL

Probesets were included in the table below when they matched the following conditions (see Suppl Fig. 1A)

AND Bcan(FN) / Control(FN) >2.00  
AND Bcan(PLL) / Control(PLL) >0.75 and <1.25  
AND Control(FN) / Control(PLL) >0.75 and <1.25

Probeset	Gene Symbol	Description	Bcan FN	Control FN	Bcan PLL	Gene ID	Cytoband	GO BIOLOGICAL PROCESS	GO MOLECULAR FUNCTION	GO CELLULAR COMPONENT
240994_at	BRE	brain and reproductive organ-expressed (TNFRSF1A modulator)	5.710	1.004	1.560	9577	2p23.2	carbohydrate metabolic pro	peroxisome targeting sequ	nuclear ubiquitin ligase comp
1553874_a_at	ZSCAN10	zinc finger and SCAN domain containing 10 (previous ZNF206)	5.389	2.126	1.076	84891	16p13.3	transcription /// regulation of	nucleic acid binding /// DNA	intracellular /// nucleus
1561616_a_at	DNAH6	dynein, axonemal, heavy polypeptide 6	4.136	1.313	1.069	1768 // 20	2p11.2	microtubule-based moveme	nucleotide binding /// motor	microtubule /// dynein comple
240262_at	CTNNA1	catenin (cadherin-associated protein), alpha 1, 102kDa	3.809	1.164	0.979	1495	5q31	cell adhesion /// cell adhesi	structural molecule activity /	cytoplasm /// cytoskeleton ///
228440_at	PET112L	pet112-like (yeast)	3.493	1.459	0.942	5188	4q27-28	translation /// translation	translation factor activity, nu	mitochondrion /// mitochondri
36554_at	ASMTL	acetylserotonin O-methyltransferase-like	3.454	1.128	0.791	8623	Xp22.3; Yp1	melatonin biosynthetic proc	O-methyltransferase activity	---
237194_at	TSPAN5	tetraspanin-5 (transmembrane 4 superfamily member 9)	3.423	1.618	1.111	10098	4q23	---	---	membrane /// integral to mem
221892_at	H6PD	hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase)	3.175	1.511	1.012	9563	1p36	carbohydrate metabolic pro	catalytic activity /// glucose-6	endoplasmic reticulum /// end
216797_at	----	Homo sapiens cDNA: FLJ23194 fis, clone REC00490	3.103	1.438	1.235	---	---	---	---	---
1569206_at	TCP11L2	t-complex 11 (mouse) like 2 (hypothetical protein MGC40368)	3.052	1.144	1.007	255394	12q23.3	---	---	---
232770_at	TUSC3	tumor suppressor candidate 3	2.954	1.044	1.389	7991	8p22	protein amino acid N-linked	dolichyl-diphosphooligosacc	endoplasmic reticulum /// end
1556122_at	RAB11B	RAB11B, member RAS oncogene family	2.893	1.257	0.981	9230	19p13.2	regulation of transcription, D	nucleotide binding /// GTPas	intracellular /// plasma membr
228486_at	SLC44A1	CDw92: solute carrier family 44, member 1	2.890	1.227	0.998	23446	9q31.2	transport /// choline transpo	choline transmembrane tran	membrane /// integral to mem
1553959_a_at	B3GALT6	UDP-gal:betagal beta 1,3-galactosyltransferase polypeptide 6	2.829	1.206	0.885	126792	1p36.33	glycosaminoglycan biosynt	galactosyltransferase activit	Golgi apparatus /// Golgi med
225453_x_at	CCDC124	coiled-coil domain containing 124 (hypothetical protein BC013949)	2.786	1.077	1.083	115098	19p13.11	---	---	---
239899_at	RNF145	ring finger protein 145 (hypothetical protein FLJ31951)	2.599	0.984	1.012	153830	5q33.3	---	protein binding /// zinc ion b	membrane /// integral to mem
63305_at	PKNOX2	PBX/knotted 1 homeobox 2	2.582	1.326	0.977	63876	chr 11	regulation of transcription, D	DNA binding /// DNA binding	nucleus /// cytoplasm /// actin
1566785_x_at	NSF	N-ethylmaleimide-sensitive factor	2.531	1.094	1.023	728806	17q21.31-q2	---	nucleotide binding /// ATP b	---
<b>201842_s_at</b>	<b>EFEMP1</b>	<b>EGF-containing fibulin-like extracellular matrix protein 1</b>	<b>2.479</b>	<b>0.982</b>	<b>0.900</b>	<b>2202</b>	<b>2p16</b>	visual perception	calcium ion binding /// prote	extracellular region /// protei
221133_s_at	CLDN18	claudin 18	2.376	0.876	1.243	51208	3q22.3	calcium-independent cell-ce	structural molecule activity /	plasma membrane /// tight jur
56256_at	SIDT2	SID1 transmembrane family, member 2	2.346	0.877	1.007	51092	11q23.3	---	---	membrane /// integral to mem
244391_at	TSEN2	tRNA splicing endonuclease 2 homolog (S. cerevisiae)	2.219	0.987	1.085	80746	3p25.1	tRNA splicing /// mRNA prot	tRNA-intron endonuclease a	tRNA-intron endonuclease co
204944_at	PTPRG	protein tyrosine phosphatase, receptor type, G	2.161	1.081	0.957	5793	3p21-p14	protein amino acid dephosp	carbonate dehydratase activ	integral to plasma membrane
1568365_at	KIFAP3	kinesin-associated protein 3	2.104	0.993	0.918	22920	1q24.2	protein complex assembly /	binding /// protein binding ///	endoplasmic reticulum /// kine
1558943_x_at	ZNF765	zinc finger protein 765 (hypothetical protein BC001610)	2.092	0.967	1.093	91661	19q13.41	regulation of transcription, D	nucleic acid binding /// zinc	intracellular
209964_s_at	ATXN7	ataxin 7	2.090	0.862	1.154	6314	3p21.1-p12	transcription /// regulation of	protein binding /// zinc ion b	intracellular /// nucleus /// nuc
201151_s_at	MBNL1	muscleblind-like (Drosophila)	2.083	0.999	0.888	4154	3q25	in utero embryonic develop	nucleic acid binding /// RNA	nucleus /// nucleus /// cytopla
222171_s_at	PKNOX2	PBX/knotted 1 homeobox 2	2.073	0.704	1.392	63876	chr 11	regulation of transcription, D	DNA binding /// DNA binding	nucleus /// cytoplasm /// actin
229366_at	CRBN	cereblon	2.009	0.992	0.975	51185	3p26.3	ATP-dependent proteolysis	ATP-dependent peptidase a	cytoplasm /// membrane
221477_s_at	SOD2	superoxide dismutase 2, mitochondrial	2.005	0.906	1.047	79099	6q25.3	response to superoxide /// r	superoxide dismutase activi	mitochondrion /// mitochondri

**SUPPLEMENTARY TABLE II**  
**ONCOMINE STUDIES**

**Expression of Fibulin-3 (EFEMP-1) mRNA (by microarray analysis) in solid tumors**

**t = (average signal in tumor - average signal in control) / standard deviation (control vs. tumor)**

**Gene Symbol:** EFEMP1

**t < 0 and p < 0.05 --> EFEMP1 significantly decreased in tumor tissue**

**t > 0 and p < 0.05 --> EFEMP1 significantly increased in tumor tissue**

Study	TISSUE	STUDY IDENTIFICATION	YEAR	# CONTROL SAMPLES	# TUMOR SAMPLES	t test value	p value	REPORTER	PLATFORM	OBSERVATIONS	LINK TO ORIGINAL STUDY
1	BLADDER	Blaveri_Bladder_2	2005	3	81	-2.268	0.144	AA875933	Stanford microarrays		<a href="#">Bladder cancer outcome and subtype</a>
2	BLADDER	Dyrskjot_Bladder_3	2004	14	40	-1.537	0.133	201842_s_at	Affymetrix U133		<a href="#">Gene expression in the urinary bladder</a>
3	BLADDER	Sanchez-Carbayo_Bladder_2	2006	48	109	-10.229	9.00E-19	201843_s_at	Affymetrix U133		<a href="#">Defining molecular profiles of poor outcome</a>
4	BRAIN	Bredel_Brain_2	2005	4	31	6.424	3.20E-07	IMAGE:1492230	IMAGE Consortium	normal brain vs glioblastoma	<a href="#">Functional network analysis reveals</a>
	BRAIN	Bredel_Brain_2	2005	4	8	3.757	0.004	IMAGE:1492230	IMAGE Consortium	normal brain vs oligodendroglioma	<a href="#">Functional network analysis reveals</a>
	BRAIN	Bredel_Brain_2	2005	4	5	2.64	0.056	IMAGE:1492230	IMAGE Consortium	normal brain vs astrocytic tumor	<a href="#">Functional network analysis reveals</a>
5	BRAIN	Bredel_Brain_3	2005	4	6	2.318	0.065	IMAGE:1492230	IMAGE Consortium	normal brain vs anapl. oligo.	<a href="#">Functional network analysis reveals</a>
6	BRAIN	French_Brain	2005	6	27	1.426	0.186	228421_s_at	Affymetrix U133	normal brain vs anapl. oligo. and astro.	<a href="#">Gene expression profiles associated with</a>
7	BRAIN	Gutmann_Brain	2002	3	8	0.495	0.648	32551_at	Affymetrix U95	normal white matter vs pilocytic astro	<a href="#">Comparative gene expression profiles</a>
8	BRAIN	Liang_Brain	2005	3	30	6.878	6.70E-04	AA875933	Stanford microarrays	normal brain vs astrocytoma	<a href="#">Gene expression profiling reveals molecular</a>
9	BRAIN	Rickman_Brain	2001	6	45	0.84	0.43	U03877_at	Affymetrix HuGeneFL	normal brain vs astrocytoma	<a href="#">Distinctive molecular profiles of high-grade</a>
10	BRAIN	Shai_Brain	2003	7	25	3.526	0.002	32551_at	Affymetrix U95	normal brain vs glioblastoma	<a href="#">Gene expression profiling identifies novel</a>
11	BRAIN	Sun_Brain	2006	23	77	8.238	5.30E-12	201842_s_at	Affymetrix U133	normal brain vs glioblastoma	<a href="#">Neuronal and glioma-derived stem cell</a>
	BRAIN	Sun_Brain	2006	23	50	-0.919	0.361	201841_s_at	Affymetrix U133	normal brain vs oligodendroglioma	<a href="#">Neuronal and glioma-derived stem cell</a>
	BRAIN	Sun_Brain	2006	23	26	5.162	7.10E-06	201842_s_at	Affymetrix U133	normal brain vs astrocytoma	<a href="#">Neuronal and glioma-derived stem cell</a>
	BRAIN	Sun_Brain	2006	23	50	2.537	0.013	201842_s_at	Affymetrix U133	normal brain vs oligodendroglioma	<a href="#">Neuronal and glioma-derived stem cell</a>
12	BREAST	Finak_Breast	2008	6	53	12.336	6.90E-09	A_23_P501007	Agilent HG 44k	Outlier data, under revision at Oncomine	<a href="#">Stromal gene expression predicts clinical</a>
13	BREAST	Karnoub_Breast	2007	15	7	-4.317	4.10E-04	201843_s_at	Affymetrix U133		<a href="#">Mesenchymal stem cells within tumors</a>
14	BREAST	Radvanyi_Breast	2005	9	47	-1.07	0.311	AA301867	Stanford microarrays		<a href="#">The gene associated with trichorhinopharyngeal</a>
15	BREAST	Richardson_Breast_2	2006	7	40	0.657	0.515	228421_s_at	Affymetrix U133		<a href="#">X chromosomal abnormalities in basaloid</a>
	BREAST	Richardson_Breast_2	2006	7	40	-7.825	8.10E-10	201843_s_at	Affymetrix U133	same study as #15, different probe	<a href="#">X chromosomal abnormalities in basaloid</a>
16	BREAST	Turashvili_Breast	2007	5	5	0.65	0.535	228421_s_at	Affymetrix U133	breast ductal tissue vs invasive ductal carcinoma	<a href="#">Novel markers for differentiation of lobular</a>
	BREAST	Turashvili_Breast	2007	5	5	-2.215	0.0065	201843_s_at	Affymetrix U133	breast lobular tissue vs inv. lobular carcinoma	<a href="#">Novel markers for differentiation of lobular</a>
	BREAST	Turashvili_Breast	2007	5	5	-0.946	0.384	201843_s_at	Affymetrix U133	same study as #16, different probe	<a href="#">Novel markers for differentiation of lobular</a>
17	COLON	Hong_Colon	2007	10	12	4.039	7.20E-04	201842_s_at	Affymetrix U133		<a href="#">A susceptibility gene set for early-onset</a>
	COLON	Hong_Colon	2007	10	12	-0.931	0.363	228421_s_at	Affymetrix U133	same study as #17, different probe	<a href="#">A susceptibility gene set for early-onset</a>
18	COLON	Notterman_Colon	2001	18	18	-2.004	0.06	U03877	Affymetrix HuGeneFL		<a href="#">Transcriptional gene expression profiles</a>
19	DIGESTIVE	Hao_Esophagus	2006	15	5	3.496	0.016	IMAGE:1492230	IMAGE Consortium	esophagus	<a href="#">Gene expression profiling reveals stem cell</a>
20	DIGESTIVE	Hippo_Gastric	2002	8	22	-1.705	0.103	U03877_at	Affymetrix HuGeneFL	gastric	<a href="#">Global gene expression analysis of Barrett's</a>
21	DIGESTIVE	Kimchi_Esophagus	2005	8	8	0.514	0.616	201843_s_at	Affymetrix U133	esophagus	<a href="#">Progression of Barretts metaplasia to adenocarcinoma</a>
	DIGESTIVE	Kimchi_Esophagus	2005	8	8	-0.22	0.831	201842_s_at	Affymetrix U133	esophagus, same as #21, different probe	<a href="#">Progression of Barretts metaplasia to adenocarcinoma</a>
22	HEAD/NECK	Cromer_Head-Neck	2004	4	34	-3.529	0.002	32551_at	Affymetrix U95		<a href="#">Identification of genes associated with head and neck</a>
23	HEAD/NECK	Ginos_Head-Neck	2004	13	41	0.788	0.435	201843_s_at	Affymetrix U133		<a href="#">Identification of a gene expression signature</a>
	HEAD/NECK	Ginos_Head-Neck	2004	13	41	-0.177	0.86	201842_s_at	Affymetrix U133	same study as #23, different probe	<a href="#">Identification of a gene expression signature</a>
24	HEAD/NECK	Pyeon_Multi-cancer	2007	14	42	2.17	0.037	228421_s_at	Affymetrix U133		<a href="#">Fundamental differences in cell cycle regulation</a>
25	HEAD/NECK	Toruner_Head-Neck	2004	4	16	-0.304	0.766	201843_s_at	Affymetrix U133		<a href="#">Association between gene expression profiles and</a>
	HEAD/NECK	Toruner_Head-Neck	2004	4	16	0.258	0.799	201842_s_at	Affymetrix U133	same study as #25, different probe	<a href="#">Association between gene expression profiles and</a>
26	LUNG	Beer_Lung	2002	10	86	-7.141	9.80E-08	U03877_at	Affymetrix HuGeneFL		<a href="#">Gene-expression profiles predict survival</a>
27	LUNG	Bhattacharjee_Lung	2001	17	139	-6.293	5.90E-08	32551_at	Affymetrix U95	normal lung vs lung adenocarcinoma	<a href="#">Classification of human lung carcinomas</a>
	LUNG	Bhattacharjee_Lung	2001	17	21	-5.649	3.30E-04	32551_at	Affymetrix U95	normal lung vs squamous cell carcinoma	<a href="#">Classification of human lung carcinomas</a>
	LUNG	Bhattacharjee_Lung	2001	17	6	-2.291	0.067	32551_at	Affymetrix U95	normal lung vs small cell lung cancer	<a href="#">Classification of human lung carcinomas</a>
	LUNG	Bhattacharjee_Lung	2001	17	20	-7.977	7.70E-09	32551_at	Affymetrix U95	normal lung vs carcinoid	<a href="#">Classification of human lung carcinomas</a>
28	LUNG	Garber_Lung	2001	6	40	-5.384	2.30E-05	IMAGE:1492230	IMAGE Consortium	normal lung vs lung adenocarcinoma	<a href="#">Diversity of gene expression in adenocarcinoma</a>
	LUNG	Garber_Lung	2001	6	13	-5.414	6.10E-05	IMAGE:1492230	IMAGE Consortium	normal lung vs squamous cell carcinoma	<a href="#">Diversity of gene expression in adenocarcinoma</a>
	LUNG	Garber_Lung	2001	6	4	-5.398	0.006	IMAGE:1492230	IMAGE Consortium	normal lung vs small cell lung cancer	<a href="#">Diversity of gene expression in adenocarcinoma</a>
	LUNG	Garber_Lung	2001	6	4	-0.274	0.801	IMAGE:1492230	IMAGE Consortium	normal lung vs large cell lung cancer	<a href="#">Diversity of gene expression in adenocarcinoma</a>
29	LUNG	Powell_Lung	2003	11	11	-5.145	1.40E-04	U03877_at	Affymetrix HuGeneFL		<a href="#">Gene expression in lung adenocarcinoma</a>
30	LUNG	Stearman_Lung	2005	19	20	-7.5	3.30E-08	32551_at	Affymetrix U95		<a href="#">Analysis of orthologous gene expression</a>
31	LUNG	Su_Lung	2007	31	31	-5.839	5.20E-07	201843_s_at	Affymetrix U133		<a href="#">Selection of DDX5 as a novel internal control</a>

32	LUNG	Wachi_Lung	2005	5	5	-8.213	1.30E-04	201843_s_at	Affymetrix U133		<a href="#">Interactome-transcriptome analysis</a>
33	LIVER	Chen_Liver	2002	7	104	-4.31	8.80E-04	IMAGE:1492230	IMAGE Consortium	benign liver disease vs hepatocell. carcinoma	<a href="#">Gene expression patterns in human</a>
	LIVER	Chen_Liver	2002	76	104	-1.983	0.049	IMAGE:1492230	IMAGE Consortium	non-tumor liver vs hepatocell. carcinoma	<a href="#">Gene expression patterns in human</a>
34	LIVER	Wurmbach_Liver	2007	10	35	2.435	0.02	201843_s_at	Affymetrix U133		<a href="#">Genome-wide molecular profiles of l</a>
35	MELANOMA	Haqq_Melanoma	2005	10	22	-5.834	9.80E-06	AA875933	Stanford microarrays		<a href="#">The gene expression signatures of r</a>
36	MELANOMA	Hoek_Melanoma	2006	3	18	1.624	0.121	201843_s_at	Affymetrix U133		<a href="#">Metastatic potential of melanomas c</a>
	MELANOMA	Hoek_Melanoma	2006	3	24	-0.441	0.674	201842_s_at	Affymetrix U133	same study as #36, different probe	<a href="#">Metastatic potential of melanomas c</a>
37	MELANOMA	Talantov_Melanoma	2005	25	45	-10.13	2.60E-14	201842_s_at	Affymetrix U133		<a href="#">Novel genes associated with malign</a>
38	OVARY	Hendrix_Ovarian	2006	4	41	-13.33	1.80E-12	201842_s_at	Affymetrix U133	ovary vs ovarian serous adenocarcinoma	<a href="#">Fibroblast growth factor 9 has onco</a>
	OVARY	Hendrix_Ovarian	2006	4	37	-13.254	3.20E-12	201842_s_at	Affymetrix U133	ovary vs ovarian endometrioid adenocarcinoma	<a href="#">Fibroblast growth factor 9 has onco</a>
	OVARY	Hendrix_Ovarian	2006	4	13	-12.011	4.70E-09	201842_s_at	Affymetrix U133	ovary vs ovarian mucinous adenocarcinoma	<a href="#">Fibroblast growth factor 9 has onco</a>
	OVARY	Hendrix_Ovarian	2006	4	8	-5.43	4.40E-04	201842_s_at	Affymetrix U133	ovary vs ovarian clear cell adenocarcinoma	<a href="#">Fibroblast growth factor 9 has onco</a>
39	OVARY	Lancaster_Ovarian	2004	3	31	-1.35	0.301	U03877_at	Affymetrix HuGeneFL		<a href="#">Gene expression patterns that char</a>
40	OVARY	Lu_Ovarian	2004	5	19	-3.81	0.015	32551_at	Affymetrix U95		<a href="#">Selection of potential markers for ep</a>
41	OVARY	Welsh_Ovarian	2001	4	28	-2.119	0.073	U03877_at	Affymetrix HuGeneFL		<a href="#">Analysis of gene expression profiles</a>
42	PANCREAS	Buchholz_Pancreas	2005	6	8	-0.669	0.517	NM_004105	Operon OligoSet 2.0		<a href="#">Transcriptome analysis of microdis</a>
43	PANCREAS	Grutzmann_Pancreas	2003	11	14	-1.764	0.094	201843_s_at	Affymetrix U133		<a href="#">Gene expression profiling of microdi</a>
44	PANCREAS	Ishikawa_Pancreas	2005	25	24	-1.396	0.169	201842_s_at	Affymetrix U133		<a href="#">Experimental trial for diagnosis of pr</a>
45	PANCREAS	Logsdon_Pancreas	2003	10	10	1.791	0.093	U03877_at	Affymetrix HuGeneFL		<a href="#">Molecular profiling of pancreatic ade</a>
46	PLEURA	Gordon_Mesothelioma	2005	5	40	3.385	0.015	201842_s_at	Affymetrix U133	mesothelioma	<a href="#">Identification of novel candidate onc</a>
47	PROSTATE	Dhanasekaran_Prostate	2001	22	59	-3.138	0.004	IMAGE:1492230	IMAGE Consortium		<a href="#">Delineation of prognostic biomarker</a>
48	PROSTATE	Dhanasekaran_Prostate_2	2004	12	25	-4.553	2.30E-04	IMAGE:1492230	IMAGE Consortium		<a href="#">Molecular profiling of human prostat</a>
49	PROSTATE	Holzbeierlein_Prostate	2003	4	23	-1.795	0.155	32551_at	Affymetrix U95		<a href="#">Gene expression analysis of human</a>
50	PROSTATE	LaTulippe_Prostate	2002	3	23	-2.242	0.107	32551_at	Affymetrix U95		<a href="#">Comprehensive gene expression an</a>
51	PROSTATE	Liu_Prostate	2006	13	44	-5.497	2.90E-05	201842_s_at	Affymetrix U133		<a href="#">Sex-determining region Y box 4 is a</a>
52	PROSTATE	Luo_Prostate	2001	9	16	-2.463	0.023	IMAGE:1492230	IMAGE Consortium		<a href="#">Human prostate cancer and benign</a>
53	PROSTATE	Luo_Prostate_2	2002	15	15	-1.968	0.06	32551_at	Affymetrix U95		<a href="#">Gene expression analysis of prostat</a>
54	PROSTATE	Magee_Prostate	2001	4	8	-0.807	0.447	U03877_at	Affymetrix HuGeneFL		<a href="#">Expression profiling reveals hepsin</a>
55	PROSTATE	Nanni_Prostate	2006	3	22	0.683	0.557	201842_s_at	Affymetrix U133		<a href="#">Epithelial-restricted gene profile of p</a>
56	PROSTATE	Singh_Prostate	2002	50	52	-2.711	0.008	32551_at	Affymetrix U95		<a href="#">Gene expression correlates of clinic</a>
57	PROSTATE	Tomlins_Prostate	2006	22	30	-0.476	0.637	IMAGE:1492230	IMAGE Consortium		<a href="#">Integrative molecular concept mode</a>
58	PROSTATE	Vanaja_Prostate	2003	8	27	0.979	0.347	228421_s_at	Affymetrix U133		<a href="#">Transcriptional silencing of zinc fing</a>
	PROSTATE	Vanaja_Prostate	2003	8	27	-3.767	0.001	201842_s_at	Affymetrix U133	same study as #58, different probe	<a href="#">Transcriptional silencing of zinc fing</a>
59	PROSTATE	Varambally_Prostate	2005	6	7	-3.005	0.025	201842_s_at	Affymetrix U133		<a href="#">Integrative genomic and proteomic</a>
60	PROSTATE	Wang_CellLine	2007	8	8	-4.913	0.001	201843_s_at	Affymetrix U133	immortalized prostate epithelium vs prostate carcinoma	<a href="#">Identification of candidate predictive</a>
61	PROSTATE	Welsh_Prostate	2001	9	25	-4.04	8.30E-04	32551_at	Affymetrix U95		<a href="#">Analysis of gene expression identifi</a>
62	PROSTATE	Yu_Prostate	2004	23	64	-4.067	2.10E-04	32551_at	Affymetrix U95		<a href="#">Gene expression alterations in prost</a>
63	RENAL	Boer_Renal	2001	162	160	-1.291	0.199	IMAGE:162112	IMAGE Consortium	kidney vs clear renal cell carcinoma	<a href="#">Identification and classification of dif</a>
	RENAL	Boer_Renal	2001	162	160	0.502	0.616	IMAGE:162112	IMAGE Consortium	kidney vs clear renal cell carcinoma	<a href="#">Identification and classification of dif</a>
	RENAL	Boer_Renal	2001	162	16	-0.322	0.755	IMAGE:162112	IMAGE Consortium	kidney vs chromophobe renal cell carcinoma	<a href="#">Identification and classification of dif</a>
	RENAL	Boer_Renal	2001	162	16	0.176	0.871	IMAGE:162112	IMAGE Consortium	kidney vs chromophobe renal cell carcinoma	<a href="#">Identification and classification of dif</a>
64	RENAL	Gumz_Renal	2007	10	10	-0.774	0.452	201843_s_at	Affymetrix U133		<a href="#">Secreted frizzled-related protein 1 lc</a>
65	RENAL	Higgins_Renal	2003	3	26	0.382	0.728	IMAGE:1492230	IMAGE Consortium		<a href="#">Gene expression patterns in renal c</a>
66	RENAL	Lenburg_Renal	2003	9	9	0.73	0.477	228421_s_at	Affymetrix U133		<a href="#">Previously unidentified changes in r</a>
	RENAL	Lenburg_Renal	2003	9	9	-0.729	0.483	201842_s_at	Affymetrix U133	same study as #66, different probe	<a href="#">Previously unidentified changes in r</a>
67	SALIV. GLAND	FriersonHF_Salivary-gland	2002	6	16	-2.228	0.041	32551_at	Affymetrix U95		<a href="#">Large scale molecular analysis iden</a>
68	SEMINOMA	Korkola_Seminoma	2006	6	91	17.763	8.10E-31	201842_s_at	Affymetrix U133		<a href="#">Down-regulation of stem cell genes.</a>
69	THYROID	Huang_Thyroid	2001	8	8	-2.491	0.028	32551_at	Affymetrix U95		<a href="#">Gene expression in papillary thyroid</a>
70	TONGUE	Talbot_Lung	2005	26	31	-1.939	0.058	32551_at	Affymetrix U95		<a href="#">Gene expression profiling allows dis</a>
71	UTERUS	Mutter_Endometrium	2001	4	10	-1.316	0.275	U03877_at	Affymetrix HuGeneFL	normal endometrium vs endometrioid adenocarcinoma	<a href="#">Global expression changes of const</a>
72	UTERUS	Pyeon_Multi-cancer	2007	8	20	-2.008	0.056	201843_s_at	Affymetrix U133	normal cervix vs cervical cancer	<a href="#">Fundamental differences in cell cycl</a>
73	UTERUS	Wong_Endometrium	2003	8	25	2.546	0.031	AA875933	Stanford microarrays	normal cervix vs cervical carcinoma	<a href="#">Expression genomics of cervical car</a>

---

[de classification by gene expression.](#)  
[lder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification.](#)  
[outcome in patients with invasive bladder cancer using oligonucleotide microarrays.](#)

[extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas.](#)  
[extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas.](#)  
[extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas.](#)  
[extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas.](#)  
[d with treatment response in oligodendrogliomas.](#)  
[le analysis of neurofibromatosis 1-associated and sporadic pilocytic astrocytomas.](#)  
[molecularly and clinically distinct subtypes of glioblastoma multiforme.](#)  
[r-grade and low-grade gliomas based on oligonucleotide microarray analysis.](#)  
[molecular subtypes of gliomas.](#)  
[cell factor induces angiogenesis within the brain.](#)  
[cell factor induces angiogenesis within the brain.](#)  
[cell factor induces angiogenesis within the brain.](#)  
[cell factor induces angiogenesis within the brain.](#)

[linical outcome in breast cancer.](#)  
[our stroma promote breast cancer metastasis.](#)  
[ophalangeal syndrome in humans is overexpressed in breast cancer.](#)  
[sal-like human breast cancer.](#)  
[sal-like human breast cancer.](#)  
[lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis.](#)  
[lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis.](#)  
[lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis.](#)

[nset colorectal cancer that integrates diverse signaling pathways: implication for tumorigenesis.](#)  
[nset colorectal cancer that integrates diverse signaling pathways: implication for tumorigenesis.](#)  
[files of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays.](#)

[tromal genes expressed in common between Barrett's esophagus and adenocarcinoma.](#)  
[gastric cancer by oligonucleotide microarrays.](#)  
[to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.](#)  
[to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.](#)

[rith tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis.](#)  
[signature associated with recurrent disease in squamous cell carcinoma of the head and neck.](#)  
[signature associated with recurrent disease in squamous cell carcinoma of the head and neck.](#)  
[le deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers.](#)  
[on profile and tumor invasion in oral squamous cell carcinoma.](#)  
[on profile and tumor invasion in oral squamous cell carcinoma.](#)

[urvival of patients with lung adenocarcinoma.](#)  
[omas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.](#)  
[omas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.](#)  
[omas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.](#)  
[omas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.](#)  
[necarcinoma of the lung.](#)  
[necarcinoma of the lung.](#)  
[necarcinoma of the lung.](#)  
[necarcinoma of the lung.](#)  
[inomas of smokers and nonsmokers.](#)  
[ssion between human pulmonary adenocarcinoma and a carcinogen-induced murine model.](#)  
[ial control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme.](#)

[reveals the high centrality of genes differentially expressed in lung cancer tissues.](#)

[liver cancers.](#)

[liver cancers.](#)

[HCV-induced dysplasia and hepatocellular carcinoma.](#)

[melanoma progression.](#)

[defined by specific gene expression profiles with no BRAF signature.](#)

[defined by specific gene expression profiles with no BRAF signature.](#)

[ant melanoma but not benign melanocytic lesions.](#)

[genic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas.](#)

[genic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas.](#)

[genic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas.](#)

[genic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas.](#)

[acterize advanced stage serous ovarian cancers.](#)

[ithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.](#)

[s in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer.](#)

[ected pancreatic intraepithelial neoplastic lesions.](#)

[issected pancreatic ductal carcinomas using high-density DNA microarrays.](#)

[ancreatic ductal carcinoma based on gene expression profiles of pancreatic ductal cells.](#)

[enocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer.](#)

[ogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.](#)

[s in prostate cancer.](#)

[te tissues: insights into gene expression patterns of prostate development during puberty.](#)

[l prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.](#)

[nalysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease.](#)

[l transforming oncogene in human prostate cancer cells.](#)

[rostatic hyperplasia: molecular dissection by gene expression profiling.](#)

[te cancers.](#)

[overexpression in prostate cancer.](#)

[rimary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer.](#)

[al prostate cancer behavior.](#)

[ling of prostate cancer progression.](#)

[er protein 185 identified by expression profiling is associated with prostate cancer progression.](#)

[er protein 185 identified by expression profiling is associated with prostate cancer progression.](#)

[nalysis of prostate cancer reveals signatures of metastatic progression.](#)

[e and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring.](#)

[es candidate markers and pharmacological targets in prostate cancer.](#)

[tate cancer predicting tumor aggression and preceding development of malignancy.](#)

[fferentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array.](#)

[fferentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array.](#)

[fferentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array.](#)

[fferentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array.](#)

[oss contributes to tumor phenotype of clear cell renal cell carcinoma.](#)

[ell carcinoma assessed by complementary DNA microarray.](#)

[renal cell carcinoma gene expression identified by parametric analysis of microarray data.](#)

[renal cell carcinoma gene expression identified by parametric analysis of microarray data.](#)

[tifies genes with altered expression in salivary adenoid cystic carcinoma.](#)

[, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors.](#)

[l carcinoma reveals highly consistent profiles.](#)

[stinction between primary and metastatic squamous cell carcinomas in the lung.](#)

[titutive and hormonally regulated genes during endometrial neoplastic transformation.](#)

[le deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers.](#)

[ncer: molecular classification and prediction of radiotherapy response by DNA microarray.](#)



**SUPPLEMENTARY TABLE III (A)**  
**REMBRANDT DATA**

Expression of Fibulin mRNA by microarray analysis, mean expression values

shaded cells: lower quality grade for transcript assignment to the reporter (reporter with annotation grade E or R) ==> vetted probesets

Unif: Unified gene expression. Results from the individual probesets were processed into splice-form based probesets, to show a gene-based view of the expression data (additional information regarding unified gene view in <http://caintegrator-info.nci.nih.gov/rembrandt>)

Significant differences against controls:

up, p<0.05
up, p<0.001
down, p<0.05
down, p<0.001

	reporter	Mean expression intensity	Geometric mean (Log2)	St. Dev. (Log 2)	Fold over control	p value
FIBULIN-1 ASTRO	201787_at	190.151	7.432	1.696	0.936	0.7885
	202994_s_at	142.518	7.079	1.507	0.893	0.5958
	202995_s_at	401.986	8.635	0.982	0.997	0.9991
	207834_at	101.476	6.594	0.724	0.814	0.0740
	207835_at	231.040	7.737	0.638	0.848	0.0881
	Unif 2192	163.697	7.249	1.691	0.955	0.8516
FIBULIN-1 GBM	201787_at	215.568	7.242	1.856	0.820	0.4295
	202994_s_at	121.095	6.623	1.808	0.651	0.0765
	202995_s_at	365.822	8.318	1.346	0.801	0.2144
	207834_at	119.098	6.633	0.877	0.836	0.1369
	207835_at	235.568	7.619	0.637	0.781	0.0051
	Unif 2192	283.714	7.057	1.857	0.836	0.4757
FIBULIN-1 MIXED	201787_at	59.956	5.921	1.695	0.328	0.0003
	202994_s_at	76.460	6.022	1.376	0.429	0.0004
	202995_s_at	342.893	8.027	0.942	0.654	0.0063
	207834_at	177.027	6.893	0.803	1.001	0.9949
	207835_at	351.159	7.832	0.382	0.906	0.6244
	Unif 2192	53.378	5.765	1.687	0.342	0.0004
FIBULIN-1 OLIGO	201787_at	81.008	6.133	1.609	0.380	0.0001
	202994_s_at	56.415	5.941	1.102	0.406	<0.0001
	202995_s_at	239.022	7.879	0.613	0.591	<0.0001
	207834_at	120.259	6.801	0.750	0.939	0.5931
	207835_at	212.895	7.717	0.520	0.836	0.0333
	Unif 2192	72.821	5.964	1.602	0.392	0.0001
FIBULIN-1 CONTROL	201787_at	270.289	7.528	1.176		
	202994_s_at	211.569	7.242	0.872		
	202995_s_at	554.702	8.639	0.562		
	207834_at	185.257	6.892	0.707		
	207835_at	382.475	7.975	0.516		
	Unif 2192	233.896	7.315	1.173		

	reporter	Mean expression intensity	Geometric mean (Log2)	St. Dev. (Log 2)	Fold over control	p value
FIBULIN-2 ASTRO	203886_s_at	32.200	5.360	1.604	0.666	0.1173
	Unif 2199	27.963	5.174	1.605	0.680	0.1381
FIBULIN-2 GBM	203886_s_at	27.704	5.278	1.656	0.629	0.0469
	Unif 2199	37.091	5.091	1.659	0.642	0.0578
FIBULIN-2 MIXED	203886_s_at	31.801	4.911	1.509	0.488	0.0268
	Unif 2199	28.495	4.748	1.508	0.506	0.0358
FIBULIN-2 OLIGO	203886_s_at	22.896	4.670	1.062	0.413	<0.0001
	Unif 2199	20.574	4.496	1.055	0.425	0.0001
FIBULIN-2 CONTROL	203886_s_at	120.630	5.946	1.649		
	Unif 2199	105.556	5.730	1.662		

	reporter	Mean expression intensity
FIBULIN-3 ASTRO	201842_s_at	6387.342
	201843_s_at	1910.852
	228421_s_at	17.304
	Unif 2202	1907.175
FIBULIN-3 GBM	201842_s_at	7211.082
	201843_s_at	2108.498
	228421_s_at	19.698
	Unif 2202	3164.583
FIBULIN-3 MIXED	201842_s_at	5297.654
	201843_s_at	1964.659
	228421_s_at	15.996
	Unif 2202	1888.352
FIBULIN-3 OLIGO	201842_s_at	2565.457
	201843_s_at	985.697
	228421_s_at	12.799
	Unif 2202	1005.107
FIBULIN-3 CONTROL	201842_s_at	2268.283
	201843_s_at	757.735
	228421_s_at	24.101
	Unif 2202	766.428

Geometric mean (Log2)	St. Dev. (Log 2)	Fold over control	p value
12.298	1.216	3.422	<0.0001
10.687	1.240	3.145	<0.0001
4.160	1.184		0.8342

10.759	1.226	3.369	<0.0001
--------	-------	-------	---------

12.089	2.007	2.961	0.0001
10.296	2.109	2.398	0.0019
4.554	1.327		0.0848

10.999	2.070	3.979	0.0014
--------	-------	-------	--------

11.599	1.592	2.108	0.0013
9.973	1.681	1.917	0.0073
3.750	1.228		0.2257

9.999	1.570	1.989	0.0028
-------	-------	-------	--------

11.297	1.343	1.710	0.0039
9.849	1.328	1.760	0.0024
3.810	0.947		0.1588

9.872	1.269	1.822	0.0008
-------	-------	-------	--------

10.523	0.432		
9.034	0.512		
4.107	0.830		

9.007	0.501		
-------	-------	--	--

	reporter	Mean expression intensity	Geometric mean (Log2)	St. Dev. (Log 2)	Fold over control	p value
FIBULIN-4	206580_s_at	927.369	9.820	0.851	1.243	0.0600
ASTRO	209356_x_at	721.572	9.441	0.917	1.260	0.0658
	Unif 30008	590.654	9.256	0.910	1.285	0.0454

FIBULIN-4	206580_s_at	1765.670	10.967	0.855	2.753	<0.0001
GBM	209356_x_at	1429.208	10.618	0.920	2.849	<0.0001
	Unif 30008	1851.738	10.432	0.913	2.902	< 0.0001

FIBULIN-4	206580_s_at	770.016	9.251	1.013	0.838	0.2057
MIXED	209356_x_at	502.096	8.790	1.148	0.803	0.1689
	Unif 30008	442.202	8.628	1.144	0.831	0.2470

FIBULIN-4	206580_s_at	535.224	9.346	0.336	0.895	0.3356
OLIGO	209356_x_at	380.565	8.850	1.033	0.837	0.2028
	Unif 30008	345.679	8.679	1.032	0.861	0.2839

FIBULIN-4	206580_s_at	1077.461	9.506	0.264		
CONTROL	209356_x_at	779.325	9.108	0.327		
	Unif 30008	665.242	8.895	0.341		

	reporter	Mean expression intensity	Geometric mean (Log2)	St. Dev. (Log 2)	Fold over control	p value
FIBULIN-5	203088_at	393.713	8.249	1.618	0.827	0.3931
ASTRO						
	Unif. 10516	222.558	7.509	1.890	0.820	0.4597

FIBULIN-5	203088_at	672.318	8.793	1.757	1.205	0.4248
GBM						
	Unif. 10516	719.082	8.237	2.027	1.358	0.2605

FIBULIN-5	203088_at	360.821	7.881	1.814	0.640	0.0920
MIXED						
	Unif. 10516	169.448	6.803	2.246	0.503	0.0467

FIBULIN-5	203088_at	180.143	7.221	1.695	0.405	0.0002
OLIGO						
	Unif. 10516	68.720	6.234	1.878	0.339	0.0001

FIBULIN-5	203088_at	599.091	8.524	0.713		
CONTROL						
	Unif. 10516	404.648	7.795	1.120		

## SUPPLEMENTARY TABLE IV

### TARGET SEQUENCES USED FOR RNA INTERFERENCE

	Target sequence
human Fibulin-3 siRNA1	5'-CACAACTGTGCCAAGACATA
human Fibulin-3 siRNA2	5'-CACGCAATGCACTGACGGATA
rat Fibulin-3 siRNA1	5'-AGGCAACAACGATTTATGCAA
rat Fibulin-3 siRNA2	5'-ATGCGTTTGCCCGGTCTCAA

### PRIMERS USED FOR RT-PCR

Primer ID	Sequence	Species specificity	Use	Comments
<b>GAPDH forward</b> <b>GAPDH reverse</b>	5'-AGTCCATGCCATCACTGCCAC 5'-ATGACCTTGCCACAGCCTTG	human / rat / mouse human / rat / mouse	qRT-PCR qRT-PCR	
<b>Fibulin-3 forward</b> <b>Fibulin-3 reverse</b>	5'-TCAGACATCTTCCAGATACAG 5'-CCCACTATTATTGTCAATCTTAA	human / rat / mouse human / rat / mouse	qRT-PCR qRT-PCR	
<b>Fibulin-3 forward</b> <b>Fibulin-3 reverse</b>	5'-TGAGGTCCTTCTGCTGGTT 5'-GGAGGATACCTCTGCCTTCC	human human	qRT-PCR qRT-PCR	independent control for Fibulin-3 expression in human specimens
<b>Fibulin-3 forward</b> <b>Fibulin-3 reverse</b>	ACATGCCACTGTCTTCTCCTGG GTTTGCTGCCAGCTGAAACC	rat rat	qRT-PCR qRT-PCR	independent control for Fibulin-3 expression in rat tissues or cell lines
<b>Fibulin-3 forward</b> <b>Fibulin-3 reverse</b>	5'-TCAGACATCTTCCAGATACAG 5'-CCCACTATTATTGTCAATCTTAA	human / rat / mouse human / rat / mouse	RT-PCR RT-PCR	multi-species specific primers for semiquantitative RT-PCR
<b>Fibulin-3 forward</b> <b>Fibulin-3 reverse</b>	5'-TCGCCAGATCAGACCCACG 5'-GAAAAGGGCTTTCAACATTGTG	human human	RT-PCR RT-PCR	used to detect splice variants of human fibulin-3 with and without the non-coding exon 2
<b>MMP2 forward</b> <b>MMP2 reverse</b>	5'-CCATCGAGACCATGCGGAAG 5'-CCTGTATGTGATCTGGTTCTTG	human / rat / mouse human / rat / mouse	qRT-PCR qRT-PCR	
<b>MMP9 forward</b> <b>MMP9 reverse</b>	5'-TCATCCAGTTTGGTGTGCGG 5'-GACCACAACCTCGTCGTCGTC	human / rat / mouse human / rat / mouse	qRT-PCR qRT-PCR	
<b>ADAMTS4 forward</b> <b>ADAMTS4 reverse</b>	5'-GTAGATTCGTGGAGACACTG 5'-ACCAAGTTGACAGGGTTTCG	rat rat	qRT-PCR qRT-PCR	
<b>ADAMTS5 forward</b> <b>ADAMTS5 reverse</b>	5'-AGCTAGGTGATGACCATGAG 5'-GGAGAACATATGGTCCCAAC	rat rat	qRT-PCR qRT-PCR	